About Von Willebrand Disease — What is VWD
Humat-P for VWD — High-Quality VWF
Using Humate-P
The CSL Behring Commitment
Resources & Tools
Home Infusion Video
Request More Information
Educational Program Links
AllAboutBleeding.com
Dosage Calculator
Customizable Patient Education Materials
VWF Densitometric Analysis
News & Events
Important Safety Information
Prescribing Information
Dosing Calculator
VWF Densitometric Analysis
Request More Information
For Patients

Customizable Patient Materials

Here you will find some of our most requested patient materials. You can customize these materials with your own office contact information and provide copies for your patients. Just follow these three steps:

  1. Click below to open the PDF file you would like to customize.
  2. Enter your office information in the spaces provided.
  3. Save the customized PDF to your desktop or print the PDF using the menu bar at the top of the form.

Medications to Avoid
This link provides a listing of medication your VWD patients should avoid.

Activities to Enjoy
This link provides information on physical activities.

My Journal
Your female patients with VWD can use this journal to keep track of their menstrual cycles and related information. It can also be a helpful tool for their next visit with you.


Important Safety Information

Antihemophilic Factor/von Willebrand Factor Complex (Human), Dried, Pasteurized, Humate-P® is indicated in adult patients for treatment and prevention of bleeding in hemophilia A (classical hemophilia). Humate-P® is also indicated in adult and pediatric patients with von Willebrand disease (VWD) for (1) treatment of spontaneous and trauma-induced bleeding episodes, and (2) prevention of excessive bleeding during and after surgery. This applies to patients with severe VWD, and patients with mild and moderate VWD for whom use of desmopressin is known or suspected to be inadequate.

Humate-P® is contraindicated in individuals with a history of anaphylactic or severe systemic response to antihemophilic factor or von Willebrand factor preparations, or to any of its components.

Thromboembolic events have been reported in VWD patients receiving coagulation factor replacement, especially in the setting of known risk factors for thrombosis. Caution should be exercised and antithrombotic measures considered.

Humate-P® is derived from human plasma. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

The most common adverse reactions reported in patients receiving Humate-P® are allergic-anaphylactic reactions, including urticaria, chest tightness, rash, pruritus, edema, shock, chills and fever, and hypervolemia. For patients undergoing surgery, the most common adverse reactions are postoperative wound or injection-site bleeding.

Please see full prescribing information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

The information provided herein is solely for use by physicians and healthcare professionals in the United States. The CSL Behring product listed may not have been approved in other countries and may not be available everywhere.